Results 11 to 20 of about 171,284 (274)

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease

Therapeutic Advances in Drug Safety, 2022
Inflammatory bowel diseases (IBDs) are chronic immune disorders of unclear etiology. Tumor necrosis factor (TNF) inhibitors are effective for IBD treatment and are cost-effective because they reduce hospital admissions and are associated with fewer ...
Shin Kashima, Koji Sawada, Kentaro Moriichi, Mikihiro Fujiya   +3 more
doaj   +1 more source

Ultra Luminous X-ray sources - new distance indicators? [PDF]

, 2018
In this paper we fit the NuSTAR and XMM-Newton data of three sources: NGC7793~P13, NGC5907~ULX1, and Circinus~ULX5. Our single model contains emission form non-spherical system: neutron star plus accretion disk directed towards observer.
Adhikari, Tek P., Beldycki, Bartosz, Bresler, Karol, Madej, Jerzy, Rozanska, Agata   +4 more
core   +2 more sources

Detection of t(7;12)(q36;p13) in paediatric leukaemia using dual colour fluorescence in situ hybridisation [PDF]

, 2015
The identification of chromosomal rearrangements is of utmost importance for the diagnosis and classification of specific leukaemia subtypes and therefore has an impact on therapy choices in individual cases.
Federico, C, Owoka, T, Saccone, S, Tosi, S, Vetter, M   +4 more
core   +2 more sources

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

Clinical Case Reports, 2022
The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐
Xenofon Baraliakos, Styliani Tsiami, Sooraj Vijayan, Haewon Jung, Nick Barkham   +4 more
doaj   +1 more source

t(12;17)(p13;p13) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on t(12;17)(p13;p13), with data on clinics, and the genes involved.
openaire   +2 more sources

Cervical vestibular evoked myogenic potentials in 3-month-old infants: Comparative characteristics and feasibility for infant vestibular screening

Frontiers in Neurology, 2022
ObjectiveWe compared the characteristics of air-conducted sound cervical vestibular evoked myogenic potential (ACS-cVEMP) and bone-conducted vibration cVEMP (BCV-cVEMP) among 3-month-old infants with normal hearing and sensorineural hearing loss (SNHL ...
Jiali Shen, Jiali Shen, Jiali Shen, Lu Wang, Lu Wang, Lu Wang, Xiaobao Ma, Xiaobao Ma, Xiaobao Ma, Zichen Chen, Jianyong Chen, Jianyong Chen, Jianyong Chen, Xueyan Wang, Kuan He, Kuan He, Kuan He, Wei Wang, Wei Wang, Wei Wang, Jin Sun, Jin Sun, Jin Sun, Qin Zhang, Qin Zhang, Qin Zhang, Min Shen, Min Shen, Min Shen, Xiangping Chen, Xiangping Chen, Xiangping Chen, Qing Zhang, Qing Zhang, Qing Zhang, Kimitaka Kaga, Maoli Duan, Maoli Duan, Jun Yang, Jun Yang, Jun Yang, Yulian Jin, Yulian Jin, Yulian Jin   +43 more
doaj   +1 more source

Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping [PDF]

, 2001
TEL/ETV6 is the first transcription factor identified that is specifically required for hematopoiesis within the bone marrow. This gene has been found to have multiple fusion partners; 35 different chromosome bands have been involved in ETV6 ...
Calasanz-Abinzano, M.J. (Maria Jose), Carlson, K. (K.), Chinwalla, V. (V.), Lahortiga, I. (Idoya), Odero, M.D. (Maria Dolores), Rowley, J.D. (Janet D.)   +5 more
core   +1 more source

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +1 more source

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Gut and Liver, 2023
Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861).
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber   +9 more
doaj   +1 more source

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

mAbs, 2021
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological
HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet   +16 more
doaj   +1 more source